Navigation Links
Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
Date:10/2/2008

DENVER, Oct. 2 /PRNewswire/ -- Matthew B. Wiener, PharmD, Chief Executive Officer of Pharmatech, Inc., was recently awarded the Outstanding Cancer Leadership Award from the Colorado Cancer Coalition. The award is being presented to Dr. Wiener for his development of the Just-In-Time (JIT) enrollment methodology for cancer clinical trials. Dr. Wiener will accept his award on the evening of October 6th, at the St. Mary's Cancer Center, which will take place during the Colorado Cancer Summit, October 6th and 7th, in Grand Junction, Colorado.

The Just-In-Time methodology has been utilized at various Pharmatech research network sites within the state of Colorado as a means to increase enrollment in cancer clinical trials for rare disease indications. The JIT strategy puts the patient first in regards to enrolling into a clinical trial, as cancer patients are treated in a more efficient manner and drug sponsors see their trials completed in a shorter time frame. Matthew Wiener states that, "It is a high honor to receive such a distinguished award from the Colorado Cancer Coalition. Their recognition of our JIT program gives the program clout within the pharmaceutical and bioscience industries."

Matthew Wiener has dedicated the past 20 years to clinical research and his JIT program has been featured in abstracts and poster presentations at annual meetings, including the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).

About Pharmatech, Inc.:

Pharmatech, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech, please visit http://www.pharmatech.com.

Key Words: Oncology, Clinical Trials, Cancer Patients, CRO, SMO, Just-In-Time, Colorado


'/>"/>
SOURCE Pharmatech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
4. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
5. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
9. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
10. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
11. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):